Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD70 antibody-drug conjugate PRO1160

An antibody-drug conjugate (ADC) consisting of a human monoclonal antibody directed against the tumor-associated antigen (TAA) cluster of differentiation 70 (CD70), conjugated via a cleavable, hydrophilic linker to the camptothecin analog exatecan, with potential antineoplastic activity. Upon administration of anti-CD70 ADC PRO1160, the anti-CD70 antibody moiety targets and binds to CD70-expressing tumor cells. Upon binding, internalization and linker cleavage, exatecan is released. Exatecan inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis. This inhibits the proliferation of CD70-expressing tumor cells. CD70, the ligand for the costimulatory receptor CD27 and a member of the tumor necrosis factor (TNF) family, is found on the surfaces of various types of cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD70 ADC PRO1160
Code name:PRO 1160
PRO-1160
PRO1160
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search